CON

Business Context and Reporting Period

Company: Concentra Group Holdings Parent, Inc. (Concentra)
Filing Date: July 26, 2024
Event: Completion of Initial Public Offering (IPO) and separation from Select Medical Corporation (Select).
Context: Concentra, formerly a wholly-owned subsidiary of Select, completed its IPO on July 26, 2024. The company entered into a Separation Agreement and various related agreements (Tax, Employee, Transition Services) with Select. Select retains approximately 82.23% ownership of Concentra Common Stock following the IPO.

Key Financial Metrics and Capital Structure

Capital Raised:

• IPO Proceeds: 22,500,000 shares sold at $23.50 per share, generating net proceeds of $499,668,750.00.
• Debt Financing (Credit Agreement): $1.25 billion in senior secured credit facilities, comprising an $850 million seven-year Term Loan and a $400 million five-year Revolving Credit Facility.
• Debt Financing (Senior Notes): $650 million aggregate principal amount of 6.875% Senior Notes due 2032.

Debt Obligations and Terms:

• Credit Agreement Interest: Term SOFR + 2.00% to 2.25% (Term Loan) or Alternate Base Rate + 1.00% to 1.25%.
• Senior Notes Interest: 6.875% per annum, payable semi-annually starting January 15, 2025.
• Promissory Note to Select: $151,893,378.70 principal issued; $72,580,878.70 paid at closing, leaving $79,312,500 outstanding. Interest rate is 3.84%.

Liquidity and Covenants:

• Leverage Ratio Covenant: Must not exceed 6.50 to 1.00 (tested quarterly).
• Prepayment Requirements: Mandatory prepayments required from asset sales and excess cash flow if leverage ratio exceeds 4.00 to 1.00.

Note: This filing is a Current Report (8-K) regarding corporate events and financing. It does not contain historical revenue, profit, cash flow, or margin data for a specific reporting period.

Material Changes Versus Prior Period

Corporate Structure: Transitioned from a wholly-owned subsidiary of Select Medical Corporation to a publicly traded independent entity (NYSE: CON).
Capitalization: Significant increase in debt capacity and equity capitalization through the IPO and new credit facilities.
Ownership: Select Medical Corporation now owns approximately 82.23% of outstanding shares, with the remaining shares held by public investors.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook: The filing focuses on the execution of the separation and financing. No specific financial guidance or revenue outlook is provided in this document.
Risks and Contingencies:

• Covenant Compliance: Failure to maintain the leverage ratio below 6.50 to 1.00 constitutes an event of default, potentially accelerating debt.
• Restrictive Covenants: The Credit Agreement and Indenture limit mergers, asset sales, additional indebtedness, dividends, and restricted payments.
• Change of Control: Triggers an event of default under the Credit Agreement and a repurchase right for Note holders at 101% of principal.
• Subordination: Senior Notes are effectively subordinated to secured indebtedness (Credit Facilities) and structurally subordinated to non-guarantor subsidiary debt.

Unusual Items: The issuance of a promissory note to Select to facilitate the return of capital, with a portion remaining outstanding pending underwriters' option exercise.

Investor Verification Checklist

• Debt Servicing Capacity: Verify the company's ability to service $1.9 billion in new debt ($1.25B credit facilities + $650M notes) given the 6.50x leverage covenant.
• Parent Company Control: Assess the implications of Select Medical Corporation retaining 82.23% ownership on corporate governance and future distribution plans.
• Transition Services: Review the 24-month Transition Services Agreement to understand operational dependencies on Select post-IPO.
• Covenant Headroom: Monitor the leverage ratio closely, as mandatory prepayments are triggered if the ratio exceeds 4.00x.
• Interest Rate Exposure: Evaluate exposure to floating rates (SOFR) on the $1.25 billion credit facilities.